• Zentalis priced an underwritten public offering of 23,000,000 common shares at USD 3.5 each.
• Gross proceeds expected at about USD 80.5 million, before underwriting discounts, commissions, and offering expenses.
• Deal expected to close Aug. 17, 2026, subject to customary closing conditions.
• Underwriters hold a 30-day option to buy up to 3,450,000 additional shares at the offering price.
• Proceeds earmarked to fund development of azenosertib, manufacturing, companion diagnostics, and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentalis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608132223PRIMZONEFULLFEED9810105) on August 14, 2026, and is solely responsible for the information contained therein.